In vitro and in vivo evaluation of a chlorin-based photosensitizer KAE® for cancer treatment.
Photodiagnosis Photodyn Ther
; 38: 102759, 2022 Jun.
Article
in En
| MEDLINE
| ID: mdl-35167988
ABSTRACT
BACKGROUND:
Photodynamic therapy (PDT) has been approved for the clinical treatment of cancers. Photosensitizer (PS) is a crucial element of PDT. In the current study, in vitro and in vivo evaluation of a chlorin-based photosensitizer KAE® was performed.METHODS:
The physicochemical characteristics of KAE® were compared with chlorin e6. The intracellular distribution of KAE® in HeLa cells was observed by laser scanning confocal microscopy. Reactive oxygen species (ROS) generation was detected through a 2', 7-dichlorodihydrofluorescein diacetate probe. The pharmacokinetics of KAE® was studied in mice. The photodynamic activities of KAE® and porphyrin based PSs were compared both in vitro and in vivo. The biosafety of KAE® in mice was evaluated by pathological section observation, blood routine examination and biochemistry assays.RESULTS:
KAE® was readily dissolved in an aqueous solvent in a clinically acceptable concentration and showed a strong absorption at around 660 nm. Most of KAE® was located in the mitochondria of the tumor cells. Compared with hematoporphyrin derivative and 5-aminolevulinic acid, KAE® displayed a higher efficiency in cell killing. Furthermore, it could be completely eliminated from mouse body in 2 days. KAE® had no toxicity to mice under the tested dosage.CONCLUSIONS:
Our results suggested that KAE® is an effective and safe PS for PDT in cancer therapy and has a promising prospect for clinical application.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Photochemotherapy
/
Porphyrins
/
Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Photodiagnosis Photodyn Ther
Journal subject:
DIAGNOSTICO POR IMAGEM
/
TERAPEUTICA
Year:
2022
Document type:
Article